Regulatory

November 7, 2022

Affibody’s partner Rallybio Announces Positive Phase 1 Results for RLYB116

Solna, Sweden, November 7, 2022. Affibody’s licensee Rallybio Corporation (Nasdaq: RLYB), has announced positive topline results from a Phase 1 single ascending dose (SAD) study in healthy participants of...

Read more

Regulatory

June 3, 2022

Affibody, ACELYRIN, and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Presented During EULAR

Solna, Sweden, Los Angeles, USA, and Shanghai, China, June 3, 2022 – ACELYRIN, INC., Affibody AB, and Inmagene Biopharmaceuticals today announced data from a 16-week, global, Phase 2 clinical...

Read more

Regulatory

May 19, 2022

Report from Annual General Meeting in Affibody Medical AB (publ)

Solna, Sweden, May 19, 2022 – Affibody Medical AB (publ) today held its Annual General Meeting. The following resolutions were adopted. Adoption of the income statement and the balance...

Read more

Non-Regulatory

May 3, 2022

Affibody, ACELYRIN, and Inmagene Bio Announce Positive Results from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis

Solna, Sweden, Los Angeles, USA, and Shanghai, China, May 3, 2022 – ACELYRIN, INC., Affibody AB, and Inmagene Biopharmaceuticals Co., Ltd., today announced that a 16-week, global, Phase 2...

Read more

Regulatory

January 12, 2022

Lokon Pharma and Affibody Initiates a Collaboration to Develop Novel Cancer Therapeutics

Uppsala and Solna, Sweden, January 12, 2022. Lokon Pharma AB, a leading biotech company in the area of immunostimulatory gene therapy for cancer delivered by uniquely engineered oncolytic viruses,...

Read more

Regulatory

December 9, 2021

Phase 2 HER2-targeting Study Presented at SABCS

Solna, Sweden, December 9, 2021. Affibody AB (“Affibody”) today announced that results of the Phase 2 study “A phase II study of 68Ga-ABY-025 PET for non-invasive quantification of HER2...

Read more

Regulatory

November 16, 2021

Affibody enters agreement with ACELYRIN for the development and commercialization of izokibep at a total deal value of USD 305 million plus royalties

Solna, Sweden, November 16, 2021. Affibody AB today announced a partnership agreement with ACELYRIN, INC., (“ACELYRIN”) to develop and commercialize izokibep, a bispecific molecule targeting interleukin-17A (IL-17), for multiple...

Read more

Regulatory

March 15, 2021

Annual Report 2021

Annual Report 2021, March 15, 2022

Read more